CHICAGO, Sept. 21 Advanced Life SciencesHoldings, Inc. (Nasdaq: ADLS), has received approval from the NASDAQ ListingsQualifications Staff to transfer the listing of its common stock to the NASDAQCapital Market from the NASDAQ Global Market. The transfer is effective as ofthe open of the Market today. The Company continues to be listed and tradedunder the symbol "ADLS."
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )
"Advanced Life Sciences currently meets all of the requirements forcontinued listing on the NASDAQ Capital Market," said Michael T. Flavin,Ph.D., chairman and chief executive officer. "We believe this transfer is inthe best interest of all shareholders and feel the lower cost and listingrequirements of the NASDAQ Capital Market better meet our needs as a publiccompany."
The NASDAQ Capital Market includes over 550 issuers of a wide range ofcapitalization sizes. A NASDAQ Capital Market security satisfies allapplicable qualification requirements for NASDAQ securities, and all companieslisted on the NASDAQ Capital Market must meet certain financial requirementsand adhere to NASDAQ's corporate governance standards.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in thediscovery, development and commercialization of novel drugs in the therapeuticareas of infection, cancer and inflammation. The Company's lead candidate,cethromycin, is a novel once-a-day antibiotic in late-stage clinicaldevelopment for the treatment of respiratory tract infections including CAP.For more information, please visit us on the web athttp://www.advancedlifesciences.com.
SOURCE Advanced Life Sciences Holdings, Inc.